Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Low-dose PCI in Stage III NSCLC
NCT04597671Phase 3Active, not recruiting
- Sponsor
- NVALT
- Start
- Dec 2021
- Primary completion
- Dec 2028
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by NVALT. Started Dec 2021; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04597671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04597671.